Reuters logo
BRIEF-Cascadian Therapeutics’ tucatinib, receives orphan drug designation from FDA
2017年6月8日 / 中午12点29分 / 4 个月前

BRIEF-Cascadian Therapeutics’ tucatinib, receives orphan drug designation from FDA

June 8 (Reuters) - Cascadian Therapeutics Inc

* Cascadian therapeutics’ lead candidate, tucatinib, receives orphan drug designation from fda for treatment of breast cancer patients with brain metastases‍​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below